35 filings
Page 2 of 2
8-K
lv3s4 lv89rlav
28 Sep 21
Entry into a Material Definitive Agreement
8:53am
8-K
pba3s5m
13 Aug 21
POINT Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Update
7:00am
8-K
7vmmcjsxl
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
8-K
y684g1my
30 Jun 21
Submission of Matters to a Vote of Security Holders
12:00am
8-K
j5j0k pmqe2
21 Jun 21
Other Events
4:04pm
8-K
1ixs abyo17si
9 Jun 21
Other Events
4:40pm
8-K
xv036yjvgy1ya 5o
4 Jun 21
POINT Biopharma Announces First Patients
4:22pm
8-K
hm0ym8x
1 Jun 21
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
4:32pm
8-K
e250sd 2ca2d5rwaw
28 Apr 21
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
5:13pm
8-K/A
u65za9vja5 lulfau2jx
18 Mar 21
Financial Statements and Exhibits
9:08am
8-K
djj10sud0ujvk9pbqmre
15 Mar 21
Public Investor Presentation Transcript
5:20pm
8-K
2zz9fm4d70 6f086pl
15 Mar 21
Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
8:19am
8-K
wy0pfh
6 Aug 20
Other Events
10:36am
8-K
5e3cujfhvq
16 Jul 20
Report of Independent Registered Public Accounting Firm
4:30pm
8-K
njkpms5jnzpo5 bb9
10 Jul 20
Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Pricing of Upsized $118 Million Initial Public Offering
5:17pm